Survival, adverse events and management of silent in-hospital coronary bypass graft occlusion

ObjectivesTo assess mid-term outcomes in patients with early silent coronary bypass occlusion.Methods292 consecutive patients who underwent isolated coronary artery bypass grafting (CABG) between July 2021 and December 2023 were included in this prospective cohort study. Silent CABG occlusion was de...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Open heart Ročník 12; číslo 2; s. e003368
Hlavní autoři:	Salikhanov, Islam, Koechlin, Luca, Gahl, Brigitta, Voehringer, Luise, Reuthebuch, Oliver, Dimanski, Daniel, Mawad, Brian M, Berdajs, Denis
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England British Cardiovascular Society 07.07.2025 BMJ Publishing Group LTD BMJ Publishing Group
Témata:	Aged Angina pectoris Aspirin Biomarkers Clinical outcomes Computed Tomography Angiography Coronary Angiography Coronary Artery Bypass Coronary Artery Bypass - adverse effects Coronary Artery Disease Coronary Artery Disease - mortality Coronary Artery Disease - surgery Coronary vessels Female Follow-Up Studies Graft Occlusion, Vascular - diagnosis Graft Occlusion, Vascular - etiology Graft Occlusion, Vascular - mortality Graft Occlusion, Vascular - therapy Heart attacks Heart surgery Hospitals Humans Incidence Ischemia Male Medical imaging Middle Aged Mortality Myocardial Infarction Original Research Patients Postoperative Complications - epidemiology Postoperative Complications - therapy Prospective Studies Risk Factors Survival analysis Survival Rate - trends Time Factors Treatment Outcome Coronary Artery Bypass Coronary Angiography Myocardial Infarction Coronary Artery Disease Computed Tomography Angiography
ISSN:	2053-3624, 2398-595X, 2053-3624
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	ObjectivesTo assess mid-term outcomes in patients with early silent coronary bypass occlusion.Methods292 consecutive patients who underwent isolated coronary artery bypass grafting (CABG) between July 2021 and December 2023 were included in this prospective cohort study. Silent CABG occlusion was defined as a bypass occlusion detected by coronary CT before discharge and without clinical suspicion of perioperative myocardial infarction. The primary endpoint was the incidence of angina-related rehospitalisation and coronary revascularisation during the follow-up. The secondary endpoint was the incidence of major adverse cardiovascular and cerebrovascular events, defined as a composite of all-cause mortality, myocardial infarction and stroke.ResultsThe mean age was 67±9.5 years, with 85.3% (n=249) being male. Early silent occlusion was identified in 25 patients (8.5%). The median hospital stay was longer in the occlusion group with 10 days (IQR 8.0–12.0), versus 8.0 days (IQR 7.0–9.0) in the non-occlusion group (p<0.001). The median follow-up duration was 14.5 (IQR 13.3–16.5) months. The incidence of angina-related rehospitalisation and revascularisation was significantly higher in patients with graft occlusion (p<0.01). Cox proportional hazards regression identified graft occlusion as a strong predictor of rehospitalisation (HR=8.55, 95% CI: 3.23 to 22.64; p<0.001) and reintervention (HR=15.12, 95% CI: 4.89 to 46.74; p<0.001), indicating nearly a 9-fold higher risk of rehospitalisation and a 15-fold increased hazard of reintervention.ConclusionIn-hospital silent graft occlusion following CABG is associated with a higher incidence of angina-related rehospitalisation and revascularisation during mid-term follow-up.Trial registration numberNCT04595630.
Bibliografie:	Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. Supplement: Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/openhrt-2025-003368). None declared.
ISSN:	2053-3624 2398-595X 2053-3624
DOI:	10.1136/openhrt-2025-003368